Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety
Tóm tắt
Từ khóa
Tài liệu tham khảo
Alterio, 2012, Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?, Chem. Rev., 112, 4421, 10.1021/cr200176r
Supuran, 2008, Carbonic anhydrases: novel therapeutic applications for inhibitors and activators, Nat. Rev. Drug Discov., 7, 168, 10.1038/nrd2467
Lomelino, 2016, Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016), Expert Opin. Ther. Pat., 26, 947, 10.1080/13543776.2016.1203904
Supuran, 2017, Advances in structure-based drug discovery of carbonic anhydrase inhibitors, Expet Opin. Drug Discov., 12, 61, 10.1080/17460441.2017.1253677
Supuran, 2015
Supuran, 2016, How many carbonic anhydrase inhibition mechanisms exist?, J. Enzym. Inhib. Med. Chem., 31, 345, 10.3109/14756366.2015.1122001
Waheed, 2017, Carbonic anhydrase XII functions in health and disease, Gene, 623, 33, 10.1016/j.gene.2017.04.027
Supuran, 2018, Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one, Med. Res. Rev., 38, 1799, 10.1002/med.21497
Alterio, 2018, Crystal structure of the human carbonic anhydrase II adduct with 1-(4-sulfamoylphenyl-ethyl)-2,4,6-triphenylpyridinium perchlorate, a membrane-impermeant, isoform selective inhibitor, J. Enzym. Inhib. Med. Chem., 33, 151, 10.1080/14756366.2017.1405263
Monti, 2013, Anticancer carbonic anhydrase inhibitors: a patent review (2008 - 2013), Expert Opin. Ther. Pat., 23, 737, 10.1517/13543776.2013.798648
Bruno, 2016, Vivo evaluation of selective carbonic anhydrase inhibitors as potential anticonvulsant agents, ChemMedChem, 11, 1812, 10.1002/cmdc.201500596
Supuran, 2012, Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity, Expet Opin. Emerg. Drugs, 17, 11, 10.1517/14728214.2012.664132
Supuran, 2008, Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity, Expet Opin. Emerg. Drugs, 13, 383, 10.1517/14728214.13.2.383
De Simone, 2009, Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates?, Chem. Biol. Drug Des., 74, 317, 10.1111/j.1747-0285.2009.00857.x
Ruusuvuori, 2014, Carbonic anhydrases and brain pH in the control of neuronal excitability, Subcell. Biochem., 75, 271, 10.1007/978-94-007-7359-2_14
Casey, 2009, Bicarbonate homeostasis in excitable tissues: role of AE3 Cl-/HCO3- exchanger and carbonic anhydrase XIV interaction, Am. J. Physiol. Cell Physiol., 297, C1091, 10.1152/ajpcell.00177.2009
Buemi, 2015, Carbonic anhydrase inhibitors: design, synthesis and structural characterization of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms, Eur. J. Med. Chem., 102, 223, 10.1016/j.ejmech.2015.07.049
De Luca, 2018, Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases, Eur. J. Med. Chem., 143, 276, 10.1016/j.ejmech.2017.11.061
Bruno, 2017, Probing molecular interactions between human carbonic anhydrases (hCAs) and a novel class of benzenesulfonamides, J. Med. Chem., 60, 4316, 10.1021/acs.jmedchem.7b00264
De Luca, 2014, Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors, Eur. J. Med. Chem., 71, 105, 10.1016/j.ejmech.2013.10.071
Gitto, 2012, Synthesis, structure-activity relationship studies, and X-ray crystallographic analysis of arylsulfonamides as potent carbonic anhydrase inhibitors, J. Med. Chem., 55, 3891, 10.1021/jm300112w
Gitto, 2011, Synthesis and biological profile of new 1,2,3,4-tetrahydroisoquinolines as selective carbonic anhydrase inhibitors, Bioorg. Med. Chem., 19, 7003, 10.1016/j.bmc.2011.10.015
Mader, 2011, Structural basis for the interaction between carbonic anhydrase and 1,2,3,4-tetrahydroisoquinolin-2-ylsulfonamides, J. Med. Chem., 54, 2522, 10.1021/jm2000213
Gitto, 2010, Identification of potent and selective human carbonic anhydrase VII (hCA VII) inhibitors, ChemMedChem, 5, 823, 10.1002/cmdc.201000044
Gitto, 2010, Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies, J. Med. Chem., 53, 2401, 10.1021/jm9014026
Gitto, 2009, Synthesis and evaluation of pharmacological profile of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides, Bioorg. Med. Chem., 17, 3659, 10.1016/j.bmc.2009.03.066
Gitto, 2011, Synthesis and biological profile of new 1,2,3,4-tetrahydroisoquinolines as selective carbonic anhydrase inhibitors, Bioorg. Med. Chem., 19, 7003, 10.1016/j.bmc.2011.10.015
Russo, 2004, Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy, Neuropharmacology, 46, 865, 10.1016/j.neuropharm.2003.11.028
De Simone, 2013, Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors, Expet Opin. Drug Discov., 8, 793, 10.1517/17460441.2013.795145
Innocenti, 2007, Carbonic anhydrase inhibitors. Inhibition of transmembrane isozymes XII (cancer-associated) and XIV with anions, Bioorg. Med. Chem. Lett, 17, 1532, 10.1016/j.bmcl.2006.12.113
Nishimori, 2005, Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides, Bioorg. Med. Chem. Lett, 15, 3828, 10.1016/j.bmcl.2005.06.055
Nishimori, 2005, Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors, J. Med. Chem., 48, 7860, 10.1021/jm050483n
Di Fiore, 2010, Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide, Bioorg. Med. Chem. Lett, 20, 5023, 10.1016/j.bmcl.2010.07.051
Buonanno, 2018, The crystal structure of a hCA VII variant provides insights into the molecular determinants responsible for its catalytic behavior, Int. J. Mol. Sci., 19, 10.3390/ijms19061571
Otwinowski, 1997, Processing of X-ray diffraction data collected in oscillation mode, Methods Enzymol., 276, 307, 10.1016/S0076-6879(97)76066-X
Eriksson, 1988, Refined structure of human carbonic anhydrase II at 2.0 A resolution, Proteins, 4, 274, 10.1002/prot.340040406
Brunger, 1998, Crystallography & NMR system: a new software suite for macromolecular structure determination, Acta Crystallogr. Sect. D Biol. Crystallogr., 54, 905, 10.1107/S0907444998003254
Brunger, 2007, Version 1.2 of the crystallography and NMR system, Nat. Protoc., 2, 2728, 10.1038/nprot.2007.406
Di Fiore, 2011, Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of N-substituted benzenesulfonamides to human isoform II, Chem. Commun., 47, 11636, 10.1039/c1cc14575d
Di Fiore, 2012, Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors, Chem. Commun., 48, 8838, 10.1039/c2cc34275h
Di Fiore, 2015, Hydroxylamine-O-sulfonamide is a versatile lead compound for the development of carbonic anhydrase inhibitors, Chem. Commun., 51, 11519, 10.1039/C5CC03711E
Jones, 1991, Improved methods for building protein models in electron density maps and the location of errors in these models, Acta Crystallogr. Section A, Found. Crystallogr., 47, 110, 10.1107/S0108767390010224